Soybean -conglycinin Induces Intestinal Immune Responses in Chicks

Conglycinin from soybean has been recognized as one of the major feed allergens. This study investigated the effects of -conglycinin-induced allergic sensitization on chicks small intestines. A total of 40 7-day-old (100 g) chicks were divided into four groups as control, -conglycinin 1 h, -conglycinin 6 h, and -conglycinin 12 h. All treatment groups were administered 60 mg of -conglycinin/chick and small intestine samples were collected. -conglycinin-induced allergic sensitization marginally damages the epithelium lining of the duodenum villi and, in addition, significantly increases the accumulation of mast cells in the lamina propria and crypt of the duodenum. Moreover, the TNF- level significantly increased in all -conglycinin groups. IL-8 and IL-2 were significantly downregulated in the 1 h group; however, there were increases for the 6 h and 12 h groups. These results suggest that -conglycinin may lead to an inflammatory response in the chicks small intestines.(AU)

Soybean -conglycinin Induces Intestinal Immune Responses in Chicks

Conglycinin from soybean has been recognized as one of the major feed allergens. This study investigated the effects of -conglycinin-induced allergic sensitization on chicks small intestines. A total of 40 7-day-old (100 g) chicks were divided into four groups as control, -conglycinin 1 h, -conglycinin 6 h, and -conglycinin 12 h. All treatment groups were administered 60 mg of -conglycinin/chick and small intestine samples were collected. -conglycinin-induced allergic sensitization marginally damages the epithelium lining of the duodenum villi and, in addition, significantly increases the accumulation of mast cells in the lamina propria and crypt of the duodenum. Moreover, the TNF- level significantly increased in all -conglycinin groups. IL-8 and IL-2 were significantly downregulated in the 1 h group; however, there were increases for the 6 h and 12 h groups. These results suggest that -conglycinin may lead to an inflammatory response in the chicks small intestines.

Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission.

Treatments for patients with hematologic malignancies not in remission are limited, but a few clinical studies have investigated the effects of salvaged unrelated cord blood transplantation (CBT). We retrospectively studied 19 patients with acute leukemia, 5 with myelodysplastic syndrome (MDS with refractory anemia with excess blasts [RAEB]), and 2 with non-Hodgkin's lymphoma who received 1 CBT unit ≤ 2 loci human leukocyte antigen (HLA)-mismatched after undergoing myeloablative conditioning regimens between July 2005 and July 2014. All of them were in non-remission before transplantation. The infused total nucleated cell (TNC) dose was 4.07 (range 2.76-6.02) × 107/kg and that of CD34⁺ stem cells was 2.08 (range 0.99-8.65) × 105/kg. All patients were engrafted with neutrophils that exceeded 0.5 × 109/L on median day +17 (range 14-37 days) and had platelet counts of >20 × 109/L on median day +35 (range 17-70 days). Sixteen patients (61.5%) experienced pre-engraftment syndrome (PES), and six (23.1%) patients progressed to acute graft-versus-host disease (GVHD). The cumulative incidence rates of II-IV acute GVHD and chronic GVHD were 50% and 26.9%, respectively. After a median follow-up of 27 months (range 5-74), 14 patients survived and 3 relapsed. The estimated 2-year overall survival (OS), disease-free survival (DFS), and non-relapse mortality (NRM) rates were 50.5%, 40.3%, and 35.2%, respectively. Salvaged CBT might be a promising modality for treating hematologic malignancies, even in patients with a high leukemia burden.

Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission

Treatments for patients with hematologic malignancies not in remission are limited, but a few clinical studies have investigated the effects of salvaged unrelated cord blood transplantation (CBT). We retrospectively studied 19 patients with acute leukemia, 5 with myelodysplastic syndrome (MDS with refractory anemia with excess blasts [RAEB]), and 2 with non-Hodgkin's lymphoma who received 1 CBT unit ≤2 loci human leukocyte antigen (HLA)-mismatched after undergoing myeloablative conditioning regimens between July 2005 and July 2014. All of them were in non-remission before transplantation. The infused total nucleated cell (TNC) dose was 4.07 (range 2.76-6.02)×107/kg and that of CD34+ stem cells was 2.08 (range 0.99-8.65)×105/kg. All patients were engrafted with neutrophils that exceeded 0.5×109/L on median day +17 (range 14-37 days) and had platelet counts of >20×109/L on median day +35 (range 17-70 days). Sixteen patients (61.5%) experienced pre-engraftment syndrome (PES), and six (23.1%) patients progressed to acute graft-versus-host disease (GVHD). The cumulative incidence rates of II-IV acute GVHD and chronic GVHD were 50% and 26.9%, respectively. After a median follow-up of 27 months (range 5-74), 14 patients survived and 3 relapsed. The estimated 2-year overall survival (OS), disease-free survival (DFS), and non-relapse mortality (NRM) rates were 50.5%, 40.3%, and 35.2%, respectively. Salvaged CBT might be a promising modality for treating hematologic malignancies, even in patients with a high leukemia burden.